May 13 |
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
|
May 13 |
Takeda shells out $100m to license AC Immune’s Phase II Alzheimer’s therapy
|
May 13 |
AC Immune rockets 47% on Alzheimer's therapy deal with Takeda
|
May 13 |
Takeda nabs option to license Alzheimer’s immunotherapies from AC Immune
|
May 13 |
Takeda Pharmaceutical, AC Immune Agree to Option and Licence Agreement, Including on Alzheimer's Treatment Candidate
|
May 13 |
AC Immune GAAP EPS of -$0.18 misses by $0.03
|
May 13 |
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
May 13 |
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
|